Dishman Carbogen Amcis Limited (DCAL) fundamentals
Dishman Carbogen Amcis Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as DCAL (ISIN INE385W01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Dishman Carbogen Amcis Limited does
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
Valuation and market data
| Last close | ₹167.25 |
|---|---|
| Market capitalisation | ₹2,580 crore |
| Enterprise value | ₹4,482 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.44 |
| Price to sales (TTM) | 0.87 |
| Book value per share | ₹377.97 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Sep 21 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,988 crore | ₹105 crore | ₹97 crore | 0.00 |
| Mar 2025 | ₹2,733 crore | ₹19 crore | ₹3 crore | 0.21 |
| Mar 2024 | ₹2,644 crore | ₹-122 crore | ₹-153 crore | -9.79 |
| Mar 2023 | ₹2,441 crore | ₹-55 crore | ₹-30 crore | -1.90 |
| Mar 2022 | ₹2,184 crore | ₹-4 crore | ₹18 crore | 1.15 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 59.3% |
|---|---|
| Foreign institutions (FII) | 6.9% |
| Mutual funds | 1.4% |
| Other domestic institutions | 0.7% |
| Retail and others | 31.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.